/CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced Health Canada has approved SKYRIZI® (risankizumab), for the treatment.
AbbVie and the University of Toronto Establish Endowed Chair in Ethnodermatology - read this article along with other careers information, tips and advice on BioSpace
100 000$ en bourses lapresse.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lapresse.ca Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
With this approval, HUMIRA, an anti-TNF monoclonal antibody, offers pediatric patients from five years of age with moderately to severely active ulcerative colitis (UC) the first subcutaneous anti-TNF treatment option
1
Approval based on results from the pivotal Phase 3 ENVISION I study, the largest clinical trial in pediatric ulcerative colitis to date, showing HUMIRA provided significant rates of response and remission both at week 8 and 52
1,2
MONTREAL, April 22, 2021 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved HUMIRA
® (adalimumab) for inducing and maintaining clinical remission in pediatric patients five years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids and/or azathioprine or 6-mercaptopurine or who are intolerant to such therapies.